| Name | Title | Contact Details |
|---|
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
CHAD Therapeutics, Inc. (CHAD) was established to develop, produce and market respiratory care devices designed to improve the efficiency of oxygen delivery systems for both home and hospital treatment of patients who require supplemental oxygen.
At Health IQ, we believe the best way to improve the health of the world is to celebrate the health conscious rather than harassing those who are not.
Queens-Long Island Medical Group, P.C. is a Garden City, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diagnostic Imaging, P.C is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.